Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission.
暂无分享,去创建一个
R. Peeling | J. Ward | Rakesh Aggarwal | J. Lazarus | B. McMahon | S. Taylor-Robinson | T. Asselah | R. Atun | M. Hellard | H. Razavi | G. Cooke | S. Hamid | G. Dore | I. Waked | M. Elsayed | M. Thursz | M. Hickman | A. Pedrana | J. Sacks | E. Gane | M. Lemoine | G. Dusheiko | S. Wiktor | Bryony Simmons | A. Abdo | R. Njouom | David L. Thomas | J. Feld | P. Ocama | Max G Griswold | J. Jia | A. Aghemo | S. Kamili | J. Doyle | J. Hou | Ben Cowie | Ella Barber | A. Hill | A. Altaf | T. Applegate | A. Getahun | P. Boulet | Y. Shimakawa | M. Butsashvili | I. Andrieux-Meyer | G. Diap | C. Gore | A. Tonganibeia | J. Howell | H. Cheinquer | E. Fajardo | O. Lesi | S. Nayagam | Louise Burrows | J. Wallace | M. Sonderup | Christopher R Jones | C. Spearman | Tin Yan Lee | T. Got | F. Wolff | D. Goldberg | N. Kravchenko | T. Roberts | J. Burry | C. Cunningham | A. de Araújo | E. Barnes | Amreen Khan | P. Vickerman | A. Reddy | S. Sarin | Sharon Hutchinson | Liudmyla Maistat | A. Thompson | Tammy Meyers Morris | Bridie E Taylor | J. Ward | D. Thomas | Mamun Al Mahtab | Pavlo Skala | J. Yau | Bandar Al-Judaibi | Zyaad Ameen | Oidov Baatarkkhuu | Erica Chan | Chelsea Chow | Alice Lee | Jioiji Malani | Marcela Silva | B. Mcmahon
[1] Laura A. Henry,et al. The Global Fund , 2021, Bringing Global Governance Home.
[2] A. Wade. Can community pharmacists treat hepatitis C virus? , 2020, The Lancet Gastroenterology & Hepatology.
[3] A. Slocum,et al. Development of a long-acting direct-acting antiviral system for hepatitis C virus treatment in swine , 2020, Proceedings of the National Academy of Sciences.
[4] J. Seeley,et al. Hepatitis B virus seroepidemiology data for Africa: Modelling intervention strategies based on a systematic review and meta-analysis , 2020, PLoS medicine.
[5] M. van der Valk,et al. Hepatitis C elimination in the Netherlands (CELINE): study protocol for nationwide retrieval of lost to follow-up patients with chronic hepatitis C , 2020, BMJ open gastroenterology.
[6] G. Macedo,et al. Elimination of Hepatitis C in Portugal: An Urban Legend? , 2020, GE - Portuguese Journal of Gastroenterology.
[7] K. Stone,et al. The Global State of Harm Reduction in Prisons , 2019, Journal of correctional health care : the official journal of the National Commission on Correctional Health Care.
[8] A. Dublineau,et al. Field evaluation of GeneXpert® (Cepheid) HCV performance for RNA quantification in a genotype 1 and 6 predominant patient population in Cambodia , 2018, Journal of viral hepatitis.
[9] B. Cowie,et al. Aiming for the elimination of viral hepatitis in Australia, New Zealand, and the Pacific Islands and Territories: Where are we now and barriers to meeting World Health Organization targets by 2030 , 2018, Journal of gastroenterology and hepatology.
[10] J. Lazarus,et al. Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework , 2018, Liver international : official journal of the International Association for the Study of the Liver.
[11] Lai Wei,et al. Management Algorithm for Interrupting Mother to Child Transmission of Hepatitis B Virus. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[12] I. Waked,et al. One step closer to elimination of hepatitis C in Egypt. , 2018, The lancet. Gastroenterology & hepatology.
[13] F. Bray,et al. The public health challenge of liver cancer in Mongolia. , 2018, The lancet. Gastroenterology & hepatology.
[14] U. d’Alessandro,et al. Development of a simple score based on HBeAg and ALT for selecting patients for HBV treatment in Africa. , 2018, Journal of hepatology.
[15] Jean-Michel Pawlotsky,et al. EASL Recommendations on Treatment of Hepatitis C 2018. , 2018, Journal of hepatology.
[16] M. Bilodeau,et al. The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver , 2018, Canadian Medical Association Journal.
[17] J. Roy,et al. Absolute Insurer Denial of Direct-Acting Antiviral Therapy for Hepatitis C: A National Specialty Pharmacy Cohort Study , 2018, Open forum infectious diseases.
[18] G. Dore,et al. Elimination of Hepatitis C Virus in Australia: Laying the Foundation. , 2018, Infectious disease clinics of North America.
[19] S. Alavian,et al. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. , 2018, The lancet. Gastroenterology & hepatology.
[20] J. Schrack,et al. The Health of America’s Aging Prison Population , 2018, Epidemiologic reviews.
[21] G. Dore,et al. Evaluation of the Xpert HCV Viral Load Finger-Stick Point-of-Care Assay , 2018, The Journal of infectious diseases.
[22] S. Nsanzimana,et al. Is hepatitis C elimination possible in sub-Saharan Africa? The case of Rwanda. , 2018, The lancet. Gastroenterology & hepatology.
[23] C. Boucher,et al. Declining Hepatitis C Virus (HCV) Incidence in Dutch Human Immunodeficiency Virus-Positive Men Who Have Sex With Men After Unrestricted Access to HCV Therapy , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[24] J. Rockstroh. Is Hepatitis C Virus Elimination in Well-Defined Patient Groups Possible? , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[25] A. Fontanet,et al. Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus , 2018, Gut.
[26] A. Dublineau,et al. Field evaluation of Xpert (Cepheid) Hepatitis C Virus assay for RNA quantification in Genotype 6 predominant patient population in Cambodia , 2018 .
[27] P. Hayes,et al. Reduction in the incidence of hepatitis C-related decompensated cirrhosis associated with national scale-up of direct-acting antiviral therapies targeting patients with advanced liver fibrosis , 2018 .
[28] S. Murad,et al. Safety and efficacy of ravidasvir plus sofosbuvir 12 weeks in noncirrhotic and 24 weeks in cirrhotic patients with hepatitis C virus genotypes 1, 2, 3 and 6: The STORM-C-1 phase II/III trial , 2018 .
[29] J. Wallace,et al. Implementation of hepatitis C cure in Australia: one year on , 2018, Journal of virus eradication.
[30] J. Lazarus,et al. Hepatitis C: The beginning of the end—key elements for successful European and national strategies to eliminate HCV in Europe , 2018, Journal of viral hepatitis.
[31] P. Read,et al. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. , 2018, The lancet. Gastroenterology & hepatology.
[32] L. Tavoschi,et al. Hepatitis B/C in the countries of the EU/EEA: a systematic review of the prevalence among at-risk groups , 2018, BMC Infectious Diseases.
[33] B. Cowie,et al. Mapping progress in chronic hepatitis B: geographic variation in prevalence, diagnosis, monitoring and treatment, 2013–15 , 2018, Australian and New Zealand journal of public health.
[34] J. Lazarus,et al. Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. , 2018, The lancet. Gastroenterology & hepatology.
[35] J. Losa,et al. Human Immunodeficiency Virus/Hepatits C Virus Coinfection in Spain: Elimination Is Feasible, but the Burden of Residual Cirrhosis Will Be Significant , 2018, Open forum infectious diseases.
[36] I. Waked,et al. Planning and prioritizing direct-acting antivirals treatment for HCV patients in countries with limited resources: Lessons from the Egyptian experience. , 2017, Journal of hepatology.
[37] M. Dickie,et al. Global Health Sector Strategy on Viral Hepatitis : What does it mean for Canadians ? , 2018 .
[38] Lanjuan Li,et al. Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update) , 2017, Journal of clinical and translational hepatology.
[39] Debrah I. Boeras,et al. Diagnostic accuracy of tests to detect hepatitis B surface antigen: a systematic review of the literature and meta-analysis , 2017, BMC Infectious Diseases.
[40] R. Peeling,et al. Diagnostic accuracy of tests to detect Hepatitis C antibody: a meta-analysis and review of the literature , 2017, BMC Infectious Diseases.
[41] R. Peeling,et al. The future of viral hepatitis testing: innovations in testing technologies and approaches , 2017, BMC Infectious Diseases.
[42] P. Easterbrook,et al. Diagnostic accuracy of serological diagnosis of hepatitis C and B using dried blood spot samples (DBS): two systematic reviews and meta-analyses , 2017, BMC Infectious Diseases.
[43] P. Easterbrook,et al. Diagnostic accuracy of detection and quantification of HBV-DNA and HCV-RNA using dried blood spot (DBS) samples – a systematic review and meta-analysis , 2017, BMC Infectious Diseases.
[44] P. Easterbrook,et al. Economic evaluation of HCV testing approaches in low and middle income countries , 2017, BMC Infectious Diseases.
[45] J. Leung,et al. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review , 2017, The Lancet. Global health.
[46] J. Leung,et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review , 2017, The Lancet. Global health.
[47] S. Asch,et al. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. , 2017, Gastroenterology.
[48] G. Dore,et al. Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: A systematic review. , 2017, The International journal on drug policy.
[49] H. Hagan,et al. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs , 2017, The Cochrane database of systematic reviews.
[50] M. Hellard,et al. Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade. , 2017, The International journal on drug policy.
[51] G. Dore,et al. Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia. , 2017, The International journal on drug policy.
[52] H. Masur,et al. Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial. , 2017, Annals of internal medicine.
[53] J. Whitcomb,et al. Geographic Disparities in Access to Syringe Services Programs Among Young Persons With Hepatitis C Virus Infection in the United States , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[54] L. Soto-Ramírez. World hepatitis day. Fighting hepatitis C in Latin America and the Caribbean; an urgent call , 2017, Journal of the International AIDS Society.
[55] A. Hogewoning,et al. Men who have sex with men starting pre-exposure prophylaxis (PrEP) are at risk of HCV infection: evidence from the Amsterdam PrEP study. , 2017, AIDS.
[56] R. Atun,et al. Innovative financing instruments for global health 2002-15: a systematic analysis. , 2017, The Lancet. Global health.
[57] A. Hill,et al. The road to elimination of hepatitis C: analysis of cures versus new infections in 91 countries , 2017, Journal of virus eradication.
[58] G. Dore,et al. Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study. , 2017, The lancet. Gastroenterology & hepatology.
[59] R. Tohme,et al. The status of hepatitis B control in the African region , 2017, The Pan African medical journal.
[60] S. Norris,et al. Outcomes from a large 10 year hepatitis C treatment programme in people who inject drugs: No effect of recent or former injecting drug use on treatment adherence or therapeutic response , 2017, PloS one.
[61] Reed J. D. Sorensen,et al. Future and potential spending on health 2015–40: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries , 2017, The Lancet.
[62] J. George,et al. Acute hepatitis A, B and C but not D is still prevalent in Mongolia: a time trend analysis , 2017, Clinical and molecular hepatology.
[63] M. Manns,et al. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. , 2017, The lancet. Gastroenterology & hepatology.
[64] K. Lasser,et al. A Hepatitis C Treatment Program Based in a Safety-Net Hospital Patient-Centered Medical Home , 2017, The Annals of Family Medicine.
[65] G. Dore,et al. HCV reinfection incidence among individuals treated for recent infection , 2017, Journal of viral hepatitis.
[66] Xiaofeng Liang,et al. Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China , 2017, Emerging infectious diseases.
[67] Marcela Contreras,et al. Progress in vaccination towards hepatitis B control and elimination in the Region of the Americas , 2017, BMC Public Health.
[68] Alan D. Lopez,et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study , 2017, JAMA oncology.
[69] I. Waked,et al. National treatment programme of hepatitis C in Egypt: Hepatitis C virus model of care , 2017, Journal of viral hepatitis.
[70] J. Mukherjee,et al. “Waiting for DAAs”: A retrospective chart review of patients with untreated hepatitis C in Rwanda , 2017, PloS one.
[71] Gamal Esmat,et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. , 2017, The lancet. Gastroenterology & hepatology.
[72] S. Sarin,et al. Point -of -care testing (POCT) in molecular diagnostics: Performance evaluation of GeneXpert HCV RNA test in diagnosing and monitoring of HCV infection. , 2017, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[73] Jinfeng Liu,et al. No response to hepatitis B vaccine in infants born to HBsAg(+) mothers is associated to the transplacental transfer of HBsAg , 2017, Infectious diseases.
[74] M. Hickman,et al. Hepatitis C virus prevention and treatment prioritization-ethical, economic and evidential dimensions of early rather than delayed treatment for people who inject drugs. , 2017, Addiction.
[75] J. Fonseca,et al. Comment to: "EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease". , 2017, Journal of hepatology.
[76] F. Laraque,et al. From Care to Cure: Demonstrating a Model of Clinical Patient Navigation for Hepatitis C Care and Treatment in High-Need Patients , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[77] S. Katz,et al. Randomized controlled trial of cash incentives or peer mentors to improve HCV linkage and treatment among HIV/HCV coinfected persons who inject drugs: the CHAMPS Study , 2017 .
[78] P. Hayes,et al. Among Cirrhotic Patients with a Hepatitis C Sustained Viral Response, the Risk of De-novo Hepatocellular Carcinoma Relates to Baseline Factors and Not the Use of Direct Acting Antivirals: Results from a Nationwide Cohort , 2017 .
[79] Hepatitis B vaccines: WHO position paper – July 2017. , 2017, Releve epidemiologique hebdomadaire.
[80] R. Mikolajczyk,et al. Time trends of chronic HBV infection over prior decades - A global analysis. , 2017, Journal of hepatology.
[81] Brian L. Strom,et al. A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report , 2017 .
[82] J. Pawlotsky,et al. EASL Recommendations on Treatment of Hepatitis C 2016. , 2017, Journal of hepatology.
[83] M. Alavi,et al. Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000-2014). , 2016, Journal of hepatology.
[84] T. Hallett,et al. Requirements for global elimination of hepatitis B: a modelling study. , 2016, The Lancet. Infectious diseases.
[85] R. Chou,et al. Interventions to optimise the care continuum for chronic viral hepatitis: a systematic review and meta-analyses. , 2016, The Lancet. Infectious diseases.
[86] T. Vos,et al. Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013. , 2016, The Lancet. Infectious diseases.
[87] K. Stone. Global state of harm reduction 2016. , 2016 .
[88] A. Lok,et al. Survey of hepatitis B knowledge and stigma among chronically infected patients and uninfected persons in Beijing, China , 2016, Liver international : official journal of the International Association for the Study of the Liver.
[89] S. Holmberg,et al. Awareness of Infection and Medical Follow-Up Among persons Testing Positive for Hepatitis C Virus — National Health and Nutrition Examination Survey, 2001‒2014 , 2016 .
[90] Ashutosh Kumar Singh,et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015 , 2016, The Lancet.
[91] Shuqin Zhang,et al. Tenofovir to Prevent Hepatitis B Transmission in Mothers With High Viral Load , 2016 .
[92] P. Easterbrook. Who to test and how to test for chronic hepatitis C infection - 2016 WHO testing guidance for low- and middle-income countries. , 2016, Journal of hepatology.
[93] R. DeMarco,et al. Knowledge and Attitudes toward HIV, Hepatitis B Virus, and Hepatitis C Virus Infection among Health-care Workers in Malawi , 2016, Asia-Pacific journal of oncology nursing.
[94] P. Easterbrook,et al. Hepatitis C: global epidemiology and strategies for control. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[95] J. Macías,et al. HCV epidemiology in high-risk groups and the risk of reinfection. , 2016, Journal of hepatology.
[96] G. Lau,et al. A hepatitis B-free generation in China: from dream to reality. , 2016, The Lancet. Infectious diseases.
[97] Eyal Oren,et al. Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015 , 2016, Lancet.
[98] Reza Assadi,et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013 , 2016, The Lancet.
[99] B. Moazen,et al. Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis in prisoners , 2016, The Lancet.
[100] A. Vigani,et al. Loss to follow-up in anti-HCV-positive patients in a Brazilian regional outpatient clinic , 2016, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.
[101] Mohamed O Ahmed,et al. Hepatitis C Virus in North Africa: An Emerging Threat , 2016, TheScientificWorldJournal.
[102] Xu Ma,et al. Seroepidemiological survey of hepatitis B virus infection among 764,460 women of childbearing age in rural China: A cross-sectional study. , 2016, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[103] H. Whittle,et al. Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) study. , 2016, The Lancet. Global health.
[104] T. Hallett,et al. Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis. , 2016, The Lancet. Global health.
[105] J. Cairns,et al. Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation , 2016, Journal of hepatology.
[106] P. Easterbrook,et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. , 2016, The Lancet. Infectious diseases.
[107] K. Leder,et al. An overview of the epidemiology of notifiable infectious diseases in Australia, 1991–2011 , 2016, Epidemiology and Infection.
[108] Shuqin Zhang,et al. Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load. , 2016, The New England journal of medicine.
[109] J. Layden,et al. A Synthesis of Hepatitis C prevalence estimates in Sub-Saharan Africa: 2000–2013 , 2016, BMC Infectious Diseases.
[110] A. Walker,et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. , 2016, Journal of hepatology.
[111] Xi Li,et al. Progress towards hepatitis B prevention through vaccination in the Western Pacific, 1990-2014. , 2016, Vaccine.
[112] M. Hellard,et al. The Potential Impact of a Hepatitis C Vaccine for People Who Inject Drugs: Is a Vaccine Needed in the Age of Direct-Acting Antivirals? , 2016, PloS one.
[113] M. Hellard,et al. A systematic review of community based hepatitis C treatment , 2016, BMC Infectious Diseases.
[114] J. Ward,et al. Identification and Clinical Management of Persons with Chronic Hepatitis C Virus Infection - Cherokee Nation, 2012-2015. , 2016, MMWR. Morbidity and mortality weekly report.
[115] K. Owusu-Edusei,et al. Cost‐effectiveness of active‐passive prophylaxis and antiviral prophylaxis during pregnancy to prevent perinatal hepatitis B virus infection , 2016, Hepatology.
[116] H. Tilg,et al. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. , 2016, Journal of hepatology.
[117] Z. Konopski,et al. Hepatitis C reinfection after sustained virological response. , 2016, Journal of hepatology.
[118] M. Hellard,et al. Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model , 2016, Gut.
[119] P. Gow,et al. Novel population‐based study finding higher than reported hepatocellular carcinoma incidence suggests an updated approach is needed , 2016, Hepatology.
[120] C. Beyrer,et al. Public health and international drug policy , 2016, The Lancet.
[121] Carla V. Rodriguez,et al. Streamlining Screening to Treatment: The Hepatitis C Cascade of Care at Kaiser Permanente Mid-Atlantic States. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[122] P. Angus,et al. The increasing burden of potentially preventable liver disease among adult liver transplant recipients: A comparative analysis of liver transplant indication by era in Australia and New Zealand , 2016, Journal of gastroenterology and hepatology.
[123] Chris Mccall. Australia commits funds to curb hepatitis C epidemic , 2016, The Lancet.
[124] J. Grefenstette,et al. Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons , 2016, Annals of Internal Medicine.
[125] R. Riley,et al. Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[126] M. Shiffman. Universal screening for chronic hepatitis C virus , 2016, Liver international : official journal of the International Association for the Study of the Liver.
[127] Bryony Simmons,et al. Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C , 2016, Journal of virus eradication.
[128] N. Terrault,et al. AASLD guidelines for treatment of chronic hepatitis B , 2016, Hepatology.
[129] H. Jones,et al. Problem drug use prevalence estimation revisited: heterogeneity in capture–recapture and the role of external evidence , 2015, Addiction.
[130] I. Waked,et al. Real-Life Results of Sofosbuvir Based Therapy for Egyptian Patients with Hepatitis C and Advanced Fibrosis-Cirrhosis , 2016 .
[131] F. Souto. Distribution of hepatitis B infection in Brazil: the epidemiological situation at the beginning of the 21 st century. , 2016, Revista da Sociedade Brasileira de Medicina Tropical.
[132] A. W. Lin,et al. Surveillance and response of hepatitis B virus in Hong Kong Special Administrative Region, 1988-2014. , 2016, Western Pacific surveillance and response journal : WPSAR.
[133] L. Nguyen,et al. Rates of Treatment Eligibility in Follow-Up of Patients with Chronic Hepatitis B (CHB) Across Various Clinical Settings Who Were Initially Ineligible at Presentation , 2016, Digestive Diseases and Sciences.
[134] J. Montaner,et al. Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs? , 2015, PloS one.
[135] B. Cowie,et al. Improving the identification of priority populations to increase hepatitis B testing rates, 2012 , 2015, BMC Public Health.
[136] M. Hellard,et al. The Cascade of Care for an Australian Community-Based Hepatitis C Treatment Service , 2015, PloS one.
[137] S. Hamid,et al. Disparity in market prices for hepatitis C virus direct-acting drugs. , 2015, The Lancet. Global health.
[138] Gérard Krause,et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013 , 2015, The Lancet.
[139] G. Dore,et al. Liver disease knowledge and acceptability of non-invasive liver fibrosis assessment among people who inject drugs in the drug and alcohol setting: The LiveRLife Study. , 2015, The International journal on drug policy.
[140] M. Hellard,et al. Recommendations for the management of hepatitis C virus infection among people who inject drugs. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[141] M. Plummer,et al. World‐wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma , 2015, Hepatology.
[142] G. Dore,et al. The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for prevention , 2015, Current opinion in HIV and AIDS.
[143] P. Msaouel,et al. Improving Hepatitis C Virus Screening Rates in Primary Care: A Targeted Intervention Using the Electronic Health Record , 2015, Journal for healthcare quality : official publication of the National Association for Healthcare Quality.
[144] G. Dore,et al. Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States , 2015, Annals of Internal Medicine.
[145] C. Thio,et al. Global elimination of mother-to-child transmission of hepatitis B: revisiting the current strategy. , 2015, The Lancet. Infectious diseases.
[146] H. Whittle,et al. Natural history of chronic HBV infection in West Africa: a longitudinal population-based study from The Gambia , 2015, Gut.
[147] N. Ford,et al. Hepatitis C seroprevalence and HIV co-infection in sub-Saharan Africa: a systematic review and meta-analysis. , 2015, The Lancet. Infectious diseases.
[148] G. Cooke,et al. The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa , 2015, Gut.
[149] H. Razavi,et al. Disease burden of chronic hepatitis C in Brazil , 2015, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.
[150] B. Cowie,et al. The cascade of care for Australians living with chronic hepatitis B: measuring access to diagnosis, management and treatment , 2015, Australian and New Zealand journal of public health.
[151] H. Razavi,et al. P1263 : Global estimate of HCV infection in the pediatric and adolescent population , 2015 .
[152] G. Cooke,et al. Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries , 2015, Journal of virus eradication.
[153] L. Abu-Raddad,et al. The Epidemiology of Hepatitis C Virus in the Maghreb Region: Systematic Review and Meta-Analyses , 2015, PloS one.
[154] N. Ford,et al. Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus , 2015, Hepatology.
[155] M. Abdel-hamid,et al. Hepatitis C virus acquisition among Egyptians: analysis of a 10‐year surveillance of acute hepatitis C , 2015, Tropical medicine & international health : TM & IH.
[156] Matt Anderson,et al. European Monitoring Centre for Drugs and Drug Addiction , 2014 .
[157] P. Pattison,et al. The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs , 2014, Hepatology.
[158] S. Kerns,et al. Social impact bonds: behavioral health opportunities. , 2014, JAMA pediatrics.
[159] M. Hellard,et al. An overview of hepatitis B prevalence, prevention, and management in the Pacific Islands and Territories , 2014, Journal of gastroenterology and hepatology.
[160] G. Lauer,et al. A prophylactic hepatitis C virus vaccine: a distant peak still worth climbing. , 2014, Journal of hepatology.
[161] H. Razavi,et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. , 2014, Journal of hepatology.
[162] B. Mayosi,et al. Health and health care in South Africa--20 years after Mandela. , 2014, The New England journal of medicine.
[163] A. Mocroft,et al. HIV and hepatitis C co-infection in Europe, Israel and Argentina: a EuroSIDA perspective , 2014, BMC Infectious Diseases.
[164] J. Lazarus,et al. Policy responses to viral hepatitis B and C among people who inject drugs in Member States of the WHO European region: a sub-analysis of the WHO 2013 global hepatitis policy survey , 2014, BMC Infectious Diseases.
[165] D. Sahota,et al. Age-specific prevalence of hepatitis B virus infection in young pregnant women, Hong Kong Special Administrative Region of China , 2014, Bulletin of the World Health Organization.
[166] H. Razavi,et al. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C‐related liver disease and costs in Australia , 2014, Journal of gastroenterology and hepatology.
[167] A. Bjork,et al. Progress Toward Prevention of Transfusion-Transmitted Hepatitis B and Hepatitis C Infection — Sub-Saharan Africa, 2000–2011 , 2014, MMWR. Morbidity and mortality weekly report.
[168] C. Umscheid,et al. The Treatment Cascade for Chronic Hepatitis C Virus Infection in the United States: A Systematic Review and Meta-Analysis , 2014, PloS one.
[169] L. Abu-Raddad,et al. Vertical Transmission of Hepatitis C Virus: Systematic Review and Meta-analysis , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[170] L. Valiquette,et al. Evolution of the Global Burden of Viral Infections from Unsafe Medical Injections, 2000–2010 , 2014, PloS one.
[171] H. Razavi,et al. The current and future disease burden of chronic hepatitis C virus infection in Egypt. , 2014, Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology.
[172] R. Dhiman. Future of therapy for Hepatitis C in India: A Matter of Accessibility and Affordability? , 2014, Journal of clinical and experimental hepatology.
[173] R. Aggarwal,et al. Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part I: Status Report of HCV Infection in India. , 2014, Journal of clinical and experimental hepatology.
[174] E. Akl,et al. WHO guidance on the prevention of viral hepatitis B and C among people who inject drugs. , 2014, The International journal on drug policy.
[175] J. Ward,et al. Hepatitis C disease burden and strategies to manage the burden (Guest Editors Mark Thursz, Gregory Dore and John Ward) , 2014, Journal of viral hepatitis.
[176] E. Nelson,et al. Hepatitis C testing and status among opioid substitution treatment clients in New South Wales , 2014, Australian and New Zealand journal of public health.
[177] N. Marwaha,et al. Current testing strategies for hepatitis C virus infection in blood donors and the way forward. , 2014, World journal of gastroenterology.
[178] J. Ward,et al. Chronic Hepatitis C Virus Infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010 , 2014, Annals of Internal Medicine.
[179] M. Hellard,et al. Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. , 2014, International journal of epidemiology.
[180] S. Hutchinson,et al. Risk of transmission associated with sharing drug injecting paraphernalia: analysis of recent hepatitis C virus (HCV) infection using cross‐sectional survey data , 2014, Journal of viral hepatitis.
[181] B. Stewart,et al. World cancer report 2014. , 2014 .
[182] Keat Hong Lee,et al. Reimbursement policies in the Asia-Pacific for chronic hepatitis B , 2014, Hepatology International.
[183] A. Pharris,et al. Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness. , 2014, The International journal on drug policy.
[184] F. Abaalkhail,et al. SASLT Practice Guidelines for the Management of Hepatitis B Virus , 2014, Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association.
[185] D. Pasta. Hepatitis C virus acquisition among Egyptians : analysis of a 10-year surveillance of acute hepatitis , 2014 .
[186] C. Beyrer,et al. What has been achieved in HIV prevention, treatment and care for people who inject drugs, 2010-2012? A review of the six highest burden countries. , 2014, The International journal on drug policy.
[187] S. Zeuzem,et al. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. , 2014, Journal of hepatology.
[188] S. Hadler,et al. Preventing hepatitis B though universal vaccination: reduction of inequalities through the GAVI China project. , 2013, Vaccine.
[189] L. Gorgos. Sexual transmission of viral hepatitis. , 2013, Infectious disease clinics of North America.
[190] B. Hajarizadeh,et al. Challenges in managing patients in Australia with chronic hepatitis B: the General Practitioners’ perspective , 2013, Australian and New Zealand journal of public health.
[191] M. Lai,et al. Thirty-year outcomes of the national hepatitis B immunization program in Taiwan. , 2013, JAMA.
[192] B. Cowie,et al. Chronic hepatitis B prevalence among Aboriginal and Torres Strait Islander Australians since universal vaccination: a systematic review and meta-analysis , 2013, BMC Infectious Diseases.
[193] M. Hellard,et al. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals , 2013, Hepatology.
[194] O. Pybus,et al. Infection Frequency of Hepatitis C Virus and IL28B Haplotypes in Papua New Guinea, Fiji, and Kiribati , 2013, PloS one.
[195] P. Vickerman,et al. Combination Interventions to Prevent HCV Transmission Among People Who Inject Drugs: Modeling the Impact of Antiviral Treatment, Needle and Syringe Programs, and Opiate Substitution Therapy , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[196] A. Hall,et al. Association of Early Age at Establishment of Chronic Hepatitis B Infection with Persistent Viral Replication, Liver Cirrhosis and Hepatocellular Carcinoma: A Systematic Review , 2013, PloS one.
[197] J. Jia,et al. Update on epidemiology of hepatitis B and C in China , 2013, Journal of gastroenterology and hepatology.
[198] K. Choi,et al. Determinants of suboptimal hepatitis B vaccine uptake among men in the Republic of Korea: where should our efforts be focused: results from cross-sectional study , 2013, BMC Infectious Diseases.
[199] M. Salminen,et al. Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening , 2013, BMC Infectious Diseases.
[200] A. Lloyd,et al. Safety and effectiveness of a nurse-led outreach program for assessment and treatment of chronic hepatitis C in the custodial setting. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[201] M. Hellard,et al. Current and emerging antiviral treatments for hepatitis C infection , 2013, British journal of clinical pharmacology.
[202] S. Laperche. Multinational assessment of blood‐borne virus testing and transfusion safety on the African continent , 2013, Transfusion.
[203] M. Turchi,et al. Prevalence and risk factors of Hepatitis C virus infection in Brazil, 2005 through 2009: a cross-sectional study , 2013, BMC Infectious Diseases.
[204] S. Hamid,et al. Population-attributable estimates for risk factors associated with hepatitis B and C: policy implications for Pakistan and other South Asian countries , 2013, Hepatology International.
[205] C. Elias,et al. Global Vaccine Action Plan 2011-2020. , 2013 .
[206] B. Vennema,et al. Social impact bonds , 2021, The Essentials of Social Finance.
[207] F. Carrilho,et al. Clinical and epidemiological aspects of hepatocellular carcinoma in Brazil. , 2013, Antiviral therapy.
[208] A. Altaf,et al. Lessons learned from a community based intervention to improve injection safety in Pakistan , 2013, BMC Research Notes.
[209] R. Atun,et al. Innovative financing for health: what is truly innovative? , 2012, The Lancet.
[210] J. Dehovitz,et al. Occupational exposure to body fluids among health care workers in Georgia. , 2012, Occupational medicine.
[211] P. Vickerman,et al. Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings. , 2012, Addiction.
[212] F. Sanai,et al. Epidemiology of Viral Hepatitis in Saudi Arabia: Are We Off the Hook? , 2012, Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association.
[213] Youxin Wang,et al. Prevalence and Factors Associated with Hepatitis B Immunization and Infection among Men Who Have Sex with Men in Beijing, China , 2012, PloS one.
[214] N. Pai,et al. Incidence of acute hepatitis C virus infection among men who have sex with men with and without HIV infection: a systematic review , 2012, Sexually Transmitted Infections.
[215] H. El‐Serag,et al. Epidemiology of viral hepatitis and hepatocellular carcinoma. , 2012, Gastroenterology.
[216] A. Spaulding,et al. Screening for HCV infection in jails. , 2012, JAMA.
[217] Gretchen A. Stevens,et al. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. , 2012, Vaccine.
[218] J. Kobayashi,et al. The relevance of Japan's hepatitis vaccine policy to national Hepatitis B prevention and control , 2012, Journal of public health policy.
[219] Gamal Esmat,et al. Progress toward prevention and control of hepatitis C virus infection--Egypt, 2001-2012. , 2012, MMWR. Morbidity and mortality weekly report.
[220] A. Wasley,et al. The Increasing Burden of Imported Chronic Hepatitis B — United States, 1974–2008 , 2011, PloS one.
[221] A. Barros,et al. Towards universal health coverage: the role of within-country wealth-related inequality in 28 countries in sub-Saharan Africa. , 2011, Bulletin of the World Health Organization.
[222] C. Weinbaum,et al. Hepatitis B vaccination coverage among high-risk adults 18-49 years, U.S., 2009. , 2011, Vaccine.
[223] B. McMahon,et al. Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch‐up immunization program , 2011, Hepatology.
[224] Louisa Degenhardt,et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews , 2011, The Lancet.
[225] Sanjeev Arora,et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. , 2011, The New England journal of medicine.
[226] D. Vlahov,et al. Changes in blood-borne infection risk among injection drug users. , 2011, The Journal of infectious diseases.
[227] H. Whittle,et al. Aetiological differences in demographical, clinical and pathological characteristics of hepatocellular carcinoma in The Gambia , 2011, Liver international : official journal of the International Association for the Study of the Liver.
[228] R. Atun,et al. Universal access to malaria medicines: innovation in financing and delivery , 2010, The Lancet.
[229] Sanjeev Arora,et al. Expanding access to hepatitis C virus treatment—Extension for Community Healthcare Outcomes (ECHO) project: Disruptive innovation in specialty care , 2010, Hepatology.
[230] T. Rhodes,et al. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. , 2010, Addiction.
[231] A. Tandon,et al. Assessing public expenditure on health from a fiscal space perspective , 2010 .
[232] B. Bell,et al. Impact of Routine Hepatitis B Immunization on the Prevalence of Chronic Hepatitis B Virus Infection in the Marshall Islands and the Federated States of Micronesia , 2010, The Pediatric infectious disease journal.
[233] A. Hall,et al. Hepatitis B treatment in resource poor settings: time for action , 2009, Tropical medicine & international health : TM & IH.
[234] Norman Gitlin,et al. Chronic hepatitis B : an update , 2010 .
[235] S. Ray,et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. , 2010, Gastroenterology.
[236] J. Kaldor,et al. Incidence and risk for acute hepatitis C infection during imprisonment in Australia , 2010, European Journal of Epidemiology.
[237] M. Abdel-hamid,et al. Injection Drug Use Is a Risk Factor for HCV Infection in Urban Egypt , 2009, PloS one.
[238] R. Atun,et al. Innovating for impact: The Affordable Medicines Facility-malaria (AMFm) , 2009, Nature Medicine.
[239] M. Rani,et al. Policy & practice Hepatitis B control by 2012 in the WHO Western Pacific Region : rationale and implications , 2009 .
[240] B. McMahon,et al. Chronic hepatitis B: Update 2009 , 2009, Hepatology.
[241] N. Danielsson,et al. Improved immunization practices reduce childhood hepatitis B infection in Tonga. , 2009, Vaccine.
[242] L. Dickinson,et al. Physician practices regarding adult hepatitis B vaccination: a national survey. , 2009, American journal of preventive medicine.
[243] S. Saab,et al. Viral Hepatitis in Incarcerated Adults: A Medical and Public Health Concern , 2009, The American Journal of Gastroenterology.
[244] Y. Kinfu,et al. The health worker shortage in Africa: are enough physicians and nurses being trained? , 2009, Bulletin of the World Health Organization.
[245] S. Vermund,et al. Hepatitis B and hepatitis C in Pakistan: prevalence and risk factors. , 2009, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[246] Organización Mundial de la Salud. Home visits for the newborn child: a strategy to improve survival , 2009 .
[247] M. Mahtab,et al. Epidemiology of hepatitis B virus in Bangladeshi general population. , 2008, Hepatobiliary & pancreatic diseases international : HBPD INT.
[248] A. Abdo,et al. Long-term protection of hepatitis B vaccine 18 years after vaccination. , 2008, The Journal of infection.
[249] L. Wen,et al. Low knowledge and high infection rates of hepatitis in Vietnamese men in Sydney. , 2008, Sexual health.
[250] G. Rezza,et al. Correlates of hepatitis C virus seropositivity in prison inmates: a meta-analysis , 2008, Journal of Epidemiology & Community Health.
[251] N. Van Cuong,et al. Implementation of and costs associated with providing a birth-dose of hepatitis B vaccine in Viet Nam. , 2008, Vaccine.
[252] R. Guy,et al. Barriers to the delivery of the hepatitis B birth dose: a study of five Papua New Guinean hospitals in 2007. , 2008, Papua and New Guinea medical journal.
[253] F. P. De la Hoz,et al. Eight years of hepatitis B vaccination in Colombia with a recombinant vaccine: factors influencing hepatitis B virus infection and effectiveness. , 2008, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[254] A. Sutanto,et al. Implementing the birth dose of hepatitis B vaccine in rural Indonesia. , 2007, Vaccine.
[255] J. Elmore,et al. Release from prison--a high risk of death for former inmates. , 2007, The New England journal of medicine.
[256] B. Bell,et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. , 2006, Journal of hepatology.
[257] Colin W Shepard,et al. Hepatitis B virus infection: epidemiology and vaccination. , 2006, Epidemiologic reviews.
[258] P. Heller. The prospects of creating 'fiscal space' for the health sector. , 2006, Health policy and planning.
[259] S. Nick,et al. Evaluation of 17 CE‐marked HBsAg assays with respect to clinical sensitivity, analytical sensitivity, and hepatitis B virus mutant detection , 2006, Journal of medical virology.
[260] 中华医学会肝病学分会、感染病学分会. The guideline of prevention and treatment for chronic hepatitis B , 2005 .
[261] Fangjun Zhou,et al. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. , 2005, International journal of epidemiology.
[262] R. Moreira,et al. High prevalence of hepatitis B virus and hepatitis D virus in the western Brazilian Amazon. , 2005, The American journal of tropical medicine and hygiene.
[263] C. Bullen,et al. The New Zealand Hepatitis B Screening Programme: screening coverage and prevalence of chronic hepatitis B infection. , 2005, The New Zealand medical journal.
[264] P. Heller. Understanding Fiscal Space , 2005, IMF Policy Discussion Papers.
[265] J. Kaldor,et al. Prisoners are at risk for hepatitis C transmission , 2004, European Journal of Epidemiology.
[266] D. Skowronski,et al. Elimination of acute hepatitis B among adolescents after one decade of an immunization program targeting Grade 6 students , 2003, The Pediatric infectious disease journal.
[267] Y. Buisson,et al. 10 year assessment of infant hepatitis B vaccination program, in the Loyalty Islands (New Caledonia). , 2003, Vaccine.
[268] B. Stewart,et al. World Cancer Report , 2003 .
[269] Malla R Rao,et al. Further evidence for association of hepatitis C infection with parenteral schistosomiasis treatment in Egypt , 2002, BMC infectious diseases.
[270] P. van Damme,et al. Hepatitis B vaccination: how to reach risk groups. , 2002, Vaccine.
[271] A. Dev,et al. A survey of Australian general practice management of hepatitis C‐infected patients from non‐English‐speaking backgrounds , 2002, Journal of gastroenterology and hepatology.
[272] A. Bradford. The Australian Immunisation Handbook , 2000 .
[273] N. Wilson,et al. The effectiveness of the infant hepatitis B immunisation program in Fiji, Kiribati, Tonga and Vanuatu. , 2000, Vaccine.
[274] E. Gotuzzo,et al. [IMPACT OF THE IMMUNIZATION PROGRAM INTEGRATED TO THE EXPANDED IMMUNIZATION PROGRAM(EPI) IN HUANTA,1994-1997] , 2000, Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru.
[275] L. Magder,et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt , 2000, The Lancet.
[276] J. McCormick,et al. Unsafe injections and the transmission of hepatitis B and C in a periurban community in Pakistan. , 2000, Bulletin of the World Health Organization.
[277] A. Al-Swailem,et al. Seroepidemiology of hepatitis B virus infection in Saudi children 8 years after a mass hepatitis B vaccination programme. , 1999, The Journal of infection.
[278] Edoardo Cervoni,et al. Hepatitis C , 1998, The Lancet.
[279] I. Gust. Epidemiology of hepatitis B infection in the Western Pacific and South East Asia. , 1996, Gut.
[280] J. Roux,et al. [Control of hepatitis B in French Polynesia with a program of systematic vaccination of newborns with the Genhevac B vaccine]. , 1996, Sante.
[281] A. Milne,et al. Kawerau revisited: hepatitis A and B seroprevalence in 1984 and 1993. , 1994, The New Zealand medical journal.
[282] A J Hall,et al. The influence of age on the development of the hepatitis B carrier state , 1993, Proceedings of the Royal Society of London. Series B: Biological Sciences.
[283] D. Vergani,et al. Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false-positive result? , 1990, The Lancet.
[284] F. Al-Faleh. Hepatitis B Infection in Saudi Arabia , 1988 .
[285] B. McMahon,et al. The control of hepatitis B virus infection with vaccine in Yupik Eskimos. Demonstration of safety, immunogenicity, and efficacy under field conditions. , 1985, American journal of epidemiology.
[286] R. Koff,et al. Contagiousness of acute hepatitis B. Secondary attack rates in household contacts. , 1977, Gastroenterology.
[287] H. Bartsch,et al. International Agency for Research on Cancer. , 1969, WHO chronicle.
[288] C. Dolea,et al. World Health Organization , 1949, International Organization.
[289] Hepatitis A vaccines WHO position paper , 2022 .